Literature DB >> 9746575

Specificity of bactericidal antibody response to serogroup B meningococcal strains in Brazilian children after immunization with an outer membrane vaccine.

L G Milagres1, M C Gorla, C T Sacchi, M M Rodrigues.   

Abstract

Pre- and postvaccination serum samples from 77 children aged 2 to 6 years, who received the Cuban BC vaccine (B:4:P1.15), were analyzed for bactericidal antibodies against a local B:4:P1.15 strain (N44/89). Sera from 16 individuals with bactericidal antibodies against the B:4:P1.15 strain were tested against 23 Brazilian isolates. These include B:4 strains of distinct serosubtypes: P1.15, P1.7,1, P1.3, P1.9, P1.nt, and a B:8,19,23:P1.16 strain. A Cuban B:4:P1.15 strain (Cu385/83) was also included in the study. The specificities of bactericidal antibodies were analyzed by using mutant strains lacking a class 1 protein (PorA protein) or a class 5 protein or both. The results indicated that PorA and class 5 proteins are the main targets recognized by the bactericidal antibodies of vaccinees. Nonetheless, a complex pattern of recognition by bactericidal antibodies was found, and vaccinees were grouped according to antibody specificity. Antibodies from some individuals recognized PorA of serosubtype P1.15. However, antibodies from these individuals could not kill all P1.15 strains tested. Antibodies from a second group recognized both PorA and class 5 proteins, and antibodies from a third group recognized an as yet unidentified target antigen. The results demonstrate the importance of determining the fine epitope specificity of bactericidal antibodies to improve the existing vaccines against B meningococci.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9746575      PMCID: PMC108586     

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  22 in total

1.  Increased resolution of lipopolysaccharides and lipooligosaccharides utilizing tricine-sodium dodecyl sulfate-polyacrylamide gel electrophoresis.

Authors:  A J Lesse; A A Campagnari; W E Bittner; M A Apicella
Journal:  J Immunol Methods       Date:  1990-01-24       Impact factor: 2.303

2.  Effect of outer membrane vesicle vaccine against group B meningococcal disease in Norway.

Authors:  G Bjune; E A Høiby; J K Grønnesby; O Arnesen; J H Fredriksen; A Halstensen; E Holten; A K Lindbak; H Nøkleby; E Rosenqvist
Journal:  Lancet       Date:  1991-11-02       Impact factor: 79.321

3.  Isolation of Neisseria meningitidis mutants deficient in class 1 (porA) and class 3 (porB) outer membrane proteins.

Authors:  J Tommassen; P Vermeij; M Struyvé; R Benz; J T Poolman
Journal:  Infect Immun       Date:  1990-05       Impact factor: 3.441

4.  Standardization and a multilaboratory comparison of Neisseria meningitidis serogroup A and C serum bactericidal assays. The Multilaboratory Study Group.

Authors:  S E Maslanka; L L Gheesling; D E Libutti; K B Donaldson; H S Harakeh; J K Dykes; F F Arhin; S J Devi; C E Frasch; J C Huang; P Kriz-Kuzemenska; R D Lemmon; M Lorange; C C Peeters; S Quataert; J Y Tai; G M Carlone
Journal:  Clin Diagn Lab Immunol       Date:  1997-03

5.  Human immune response to meningococcal outer membrane protein epitopes after natural infection or vaccination.

Authors:  R E Mandrell; W D Zollinger
Journal:  Infect Immun       Date:  1989-05       Impact factor: 3.441

6.  Ongoing group B Neisseria meningitidis epidemic in São Paulo, Brazil, due to increased prevalence of a single clone of the ET-5 complex.

Authors:  C T Sacchi; L L Pessoa; S R Ramos; L G Milagres; M C Camargo; N T Hidalgo; C E Melles; D A Caugant; C E Frasch
Journal:  J Clin Microbiol       Date:  1992-07       Impact factor: 5.948

7.  Protective efficacy of a serogroup B meningococcal vaccine in Sao Paulo, Brazil.

Authors:  J C de Moraes; B A Perkins; M C Camargo; N T Hidalgo; H A Barbosa; C T Sacchi; I M Landgraf; V L Gattas; H de G Vasconcelos; I M Gral
Journal:  Lancet       Date:  1992-10-31       Impact factor: 79.321

8.  Human monoclonal antibodies against an epitope on the class 5c outer membrane protein common to many pathogenic strains of Neisseria meningitidis.

Authors:  M E Fernández de Cossío; M Ohlin; M Llano; B Selander; S Cruz; J del Valle; C A Borrebaeck
Journal:  J Infect Dis       Date:  1992-12       Impact factor: 5.226

9.  Antibodies to meningococcal class 1 outer membrane proteins in South African complement-deficient and complement-sufficient subjects.

Authors:  A Orren; R E Warren; P C Potter; A M Jones; P J Lachmann; J T Poolman
Journal:  Infect Immun       Date:  1992-11       Impact factor: 3.441

10.  Human immunity to the meningococcus. I. The role of humoral antibodies.

Authors:  I Goldschneider; E C Gotschlich; M S Artenstein
Journal:  J Exp Med       Date:  1969-06-01       Impact factor: 14.307

View more
  26 in total

1.  Multiple mechanisms of phase variation of PorA in Neisseria meningitidis.

Authors:  A van der Ende; C T Hopman; J Dankert
Journal:  Infect Immun       Date:  2000-12       Impact factor: 3.441

2.  Protection by meningococcal outer membrane protein PorA-specific antibodies and a serogroup B capsular polysaccharide-specific antibody in complement-sufficient and C6-deficient infant rats.

Authors:  Maija Toropainen; Leena Saarinen; Gestur Vidarsson; Helena Käyhty
Journal:  Infect Immun       Date:  2006-05       Impact factor: 3.441

3.  Construction and functional activities of chimeric mouse-human immunoglobulin G and immunoglobulin M antibodies against the Neisseria meningitidis PorA P1.7 and P1.16 epitopes.

Authors:  Terje E Michaelsen; Øistein Ihle; Karen Johanne Beckstrøm; Tove K Herstad; Jan Kolberg; E Arne Høiby; Audun Aase
Journal:  Infect Immun       Date:  2003-10       Impact factor: 3.441

4.  Selection of diverse strains to assess broad coverage of the bivalent FHbp meningococcal B vaccine.

Authors:  Shannon L Harris; Cuiwen Tan; John Perez; David Radley; Kathrin U Jansen; Annaliesa S Anderson; Thomas R Jones
Journal:  NPJ Vaccines       Date:  2020-01-29       Impact factor: 7.344

5.  Serosubtypes and PorA types of Neisseria meningitidis serogroup B isolated in Brazil during 1997--1998: overview and implications for vaccine development.

Authors:  C T Sacchi; A P Lemos; T Popovic; J C De Morais; A M Whitney; C E Melles; L M Brondi; L M Monteiro; M V Paiva; C A Solari; L W Mayer
Journal:  J Clin Microbiol       Date:  2001-08       Impact factor: 5.948

6.  The Neisseria meningitidis macrophage infectivity potentiator protein induces cross-strain serum bactericidal activity and is a potential serogroup B vaccine candidate.

Authors:  Miao-Chiu Hung; Omar Salim; Jeannette N Williams; John E Heckels; Myron Christodoulides
Journal:  Infect Immun       Date:  2011-06-27       Impact factor: 3.441

Review 7.  Meningococcal vaccines.

Authors:  Jens U Rüggeberg; Andrew J Pollard
Journal:  Paediatr Drugs       Date:  2004       Impact factor: 3.022

8.  The influence of genomics and proteomics on the development of potential vaccines against meningococcal infection.

Authors:  John E Heckels; Jeannette N Williams
Journal:  Genome Med       Date:  2010-07-22       Impact factor: 11.117

Review 9.  Pathogenic neisseriae: surface modulation, pathogenesis and infection control.

Authors:  Mumtaz Virji
Journal:  Nat Rev Microbiol       Date:  2009-04       Impact factor: 60.633

10.  Rectification properties and pH-dependent selectivity of meningococcal class 1 porin.

Authors:  Javier Cervera; Alexander G Komarov; Vicente M Aguilella
Journal:  Biophys J       Date:  2007-10-26       Impact factor: 4.033

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.